The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitro

Anticancer Research

Volumn 23, Issue 4, 2003, Pages 3199-3206

  Brooks, Andrew C ^a   Kanthou, Chryso ^a   Cook, Ian H ^a   Tozer, Gillian M ^a   Barber, Paul R ^c   Vojnovic, Boris ^c   Nash, Gerard B ^b   Parkins, Charles S ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c NONE

Author keywords

Binding agents; Endothelial cells; Neutrophil adhesion; Tubulin; Tumour; Vascular targeting

Indexed keywords

ANTIBODY; CELL ADHESION MOLECULE; COLCHICINE; COMBRETASTATIN A4; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; PACLITAXEL; PADGEM PROTEIN; PHOSPHATE;

ARTICLE; CELL ACTIVITY; CELL ASSAY; CELL INTERACTION; CELL STRAIN; CONTROLLED STUDY; CYTOSKELETON; DRUG TARGETING; ENDOTHELIUM CELL; EXPOSURE; FLOW MEASUREMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IN VITRO STUDY; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STATISTICAL SIGNIFICANCE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL ADHESION; CELL ADHESION MOLECULES; CELL COMMUNICATION; CELLS, CULTURED; COLCHICINE; ENDOTHELIUM, VASCULAR; HUMANS; NEUTROPHIL INFILTRATION; NEUTROPHILS; PACLITAXEL; STILBENES; TUBULIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0043031136     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1990.
2. Denekamp J: The tumour microcirculation as a target in cancer therapy: a clearer perspective. Eur J Clin Invest 29: 733-6, 1999.
3. Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR, Dennis MF and Chaplin DJ: Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 59: 1626-34, 1999.
4. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS and Garcia-Kendall D: Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 45: 209-11, 1989.
5. Woods JA, Hadfield JA, Pettit GR, Fox BW and McGown AT: The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Br J Cancer 71: 705-11, 1995.
6. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR and Chaplin DJ: Combretastatin A-4, an agent that displays potent and selective toxicity toward tumour vasculature. Cancer Research 57: 1829-1834, 1997.
7. Iyer S, Chaplin DJ, Rosenthal DS, Boulares AH, Li LY and Smulson ME: Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res 58: 4510-4, 1998.
8. Kanthou C and Tozer GM: The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 99: 2060-9, 2002.
9. Watts ME, Woodcock M, Arnold S and Chaplin DJ: Effects of novel and conventional anti-cancer agents on human endothelial permeability: influence of tumour secreted factors. Anticancer Res 17: 71-5, 1997.
10. Weiss M: Tissue destruction by neutrophils. New England J Med 320: 365-376, 1989.
11. Parkins CS, Holder AL, Hill SA, Chaplin DJ and Tozer GM: Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide. Br J Cancer 83: 811-816, 2000.
12. Cecic I, Parkins CS and Korbelik M: Induction of systemic neutrophil response in mice by photodynamic therapy of solid tumors. Photochem Photobiol 74: 712-20, 2001.
13. Mantovani A, Bussolino F and Dejana E: Cytokine regulation of endothelial cell function. FASEB J 6: 2591-9, 1992.
14. Ley K: Molecular mechanisms of leukocyte recruitment in the inflammatory process. Cardiovasc Res 32: 733-42,1996.
15. Cooke BM, Usami S, Perry I and Nash GB: A simplified method for culture of endothelial cells and analysis of adhesion of blood cells under conditions of flow. Microvascular Res 45: 33-45, 1993.
16. Rainger GE, Rowley AF and Nash GB: Adhesion-dependent release of elastase from human neutrophils in a novel, flow-based model: specificity of different chemotactic agents. Blood 92: 4819-27, 1998.
17. Luu NT, Rainger GE and Nash GB: Kinetics of the different steps during neutrophil migration through cultured endothelial monolayers treated with tumour necrosis factor-alpha. J Vasc Res 36: 477-85, 1999.
18. Parkins CS, Dennis MF, Stratford MRL, Hill SA and Chaplin DJ: Ischemia reperfusion injury in tumours: The role of oxygen radicals and nitric oxide. Cancer Research 55: 6026-6029,1995.
19. Jung U and Ley K: Regulation of E-selectin, P-selectin, and intercellular adhesion molecule 1 expression in mouse cremaster muscle vasculature. Microcirculation 4: 311-9, 1997.
20. Kaplanski G, Farnarier C, Tissot O, Pierres A, Benoliel AM, Alessi MC, Kaplanski S and Bongrand P: Granulocyte-endothelium initial adhesion. Analysis of transient binding events mediated by E-selectin in a laminar shear flow. Biophys J 64: 1922-33, 1993.
21. Bahra P, Rainger GE, Wautier JL, Nguyet-Thin L and Nash GB: Each step during transendothelial migration of flowing neutrophils is regulated by the stimulatory concentration of tumour necrosis factor-alpha. Cell Adhes Commun 6: 491-501, 1998.
22. Stocker CJ, Sugars KL, Harari OA, Landis RC, Morley BJ and Haskard DO: TNF-alpha, IL-4, and IFN-gamma regulate differential expression of P- and E-selectin expression by porcine aortic endothelial cells. J Immunol 164: 3309-15, 2000.
23. Pan J, Xia L and McEver RP: Comparison of promoters for the murine and human P-selectin genes suggests species-specific and conserved mechanisms for transcriptional regulation in endothelial cells. J Biol Chem 273: 10058-67, 1998.
24. Luscinskas FW, Ding H, Tan P, Cumming D, Tedder TF and Gerritsen ME: L- and P-selectins, but not CD49d (VLA-4) integrins, mediate monocyte initial attachment to TNF-alpha-activated vascular endothelium under flow in vitro. J Immunol 157: 326-35, 1996.
25. Kielbassa K, Schmitz C and Gerke V. Disruption of endothelial microfilaments selectively reduces the transendothelial migration of monocytes. Exp Cell Res 243: 129-41, 1998.
26. Lin CM, Ho HH, Pettit GR and Hamel E: Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry 28: 6984-91, 1989.
27. Mason K, Staab A, Hunter N, McBride W, Petersen S, Terry N and Milas L: Enhancement of tumor radioresponse by docetaxel: Involvement of immune system. Int J Oncol 18: 599-606, 2001.
28. Griffin R, Lee S, Rood K, Stewart M, Lyons J, Lew Y, Park H and Song, C: Use of arsenic trioxide as an antivascular and thermosenitizing agent in solid tumours. Neoplasia 2(6): 555-560, 2000.
29. Barchowsky A, Roussel R, Klei L, James P, Ganju N, Smith K and Dudek E: Low levels of arsenic trioxide stimulate proliferative signals in primary vascular cells without activationg stress effector pathways. Toxicol Appl Pharmacol 159(1): 65-75, 1999.
30. Perona R, Montaner S, Saniger L, Sanchez-Perez I, Bravo R and Lacal JC: Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 I proteins. Genes Dev 11: 463-75, 1997.
31. Kokura S, Rhoads CA, Wolf RE, Yoshikawa T, Granger DN and Aw TY: NF kappa b signaling in posthypoxic endothelial cells: relevance to E- selectin expression and neutrophil adhesion. J Vasc Res 38: 47-58, 2001.